Premium
Anti‐asthmatic of Lactobacillus Paracasei subsp. Paracasei NTU101 in OVA ‐induced asthmatic mice
Author(s) -
Huang WeiKai,
Cai JunHan,
Koriui Mallikarjuna,
Huang HuiYu
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1057.10
Subject(s) - lactobacillus paracasei , immunoglobulin e , splenocyte , eosinophil , ovalbumin , immunology , asthma , lactobacillus casei , methacholine , cytokine , medicine , microbiology and biotechnology , lactobacillus , chemistry , biology , lung , immune system , antibody , respiratory disease , food science , fermentation
Recent research studies have demonstrated that certain strains of LAB, particularly strains from the genera Lactobacillus showed several health promoting effects in humans and animals. The present study aimed to evaluateon Lactobacillus Paracasei subsp. Paracasei NTU101in anti‐asthmatic effect in OVA ‐induced asthmatic mice.40 OVA‐induced asthmatic BALB/c mice were equally divided into 4 groups ( control, different concentrations of NTU101, 1X, 2X, 10X). Respective mice received NTU101 for 8 weeks. The anti‐asthmatic effect of NTU101 was determined by oserving eosinophil recruitment, airway hyper‐responsiveness, TH2 cytokine and IgE levels. The NTU101 treatment effectively reduced the percentage of eosinophils in BALF when compared to the level in OVA‐induced mice. The NTU101 treatment also suppressed AHR‐induced by aerosolized methacholine. Futhermore, NTU treatment suppressed the serum IgE level and decreased Th2 cytokine in the supernatant of cultured splenocytes. These result suggest that NTU101 may have therapeutic potential against asthma.